Next-Gen Oncology Drugs Set New Standards in Cancer TreatmentThe Global Cancer/Oncology Drugs Market is valued at USD 183.4 ...

The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...

VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 6, 2026 / Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in ...

Novel capsid technology to enable convenient delivery in the doctor’s office of IKAR-003 for intermediate AMD, designed to prevent progression to sight-threatening diseaseNORWICH, England & ...

Human Microbiome Market OverviewThe human microbiome market is witnessing exceptional momentum and is projected to grow at an impressive CAGR of 31% over the forecast period.Key Request a free sample ...

Market OverviewThe global ostomy devices market is projected to grow at a healthy rate of 4–5% and is expected to reach approximately USD 3.2 billion by 2026. This steady expansion is driven by rising ...

A Comprehensive OverviewThe global Peptide Cancer Vaccine Market is valued at USD 1.2 Billion in 2025 and is projected to reach a value of USD 15.72 Billion by 2035 at a CAGR (Compound Annual Growth ...

Global Life Science Consulting Services Market OverviewThe global life science consulting services market is projected to ...

FutureWise Research, a leading global market intelligence firm specialising in healthcare and medical devices, today ...

Encouraging anti-tumour activity seen across all dose levels and in various tumour indicationsClinical benefit rate of 80% for 10 patients with HER2+ oesophageal cancer who had received prior therapy ...

Ad hoc announcement pursuant to Art. 53 LR Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent EP4615820 – “Crystalline Forms of Evenamide” is ...

LQT-23 is a potent, highly differentiated, first-in-class allosteric small molecule inhibitor of MSH3/MutSβ Unique mechanism of action with potential to slow or stop the progression of HD Cambridge, ...